Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine sulfate for prevention of COVID-19 in high- and low-prevalence communities
ChiCTR2000032487Phase 4Not yet recruiting
- Sponsor
- Shanghai Public Health Clinical Center
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shanghai Public Health Clinical Center. Primary endpoint: Detection of nucleic acid and antibody of new coronavirus. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000032487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032487.